Where open innovation partnership matters: Phase-specific patterns in R&D project counts for large pharmaceutical firms

Firms are increasingly leveraging open innovation (OI) partnership to access external knowledge and navigate scientific and regulatory challenges. However, large firms differ in how strongly they emphasize OI in public communications, and the implications for various phases of the R&D pipeline remain unclear. This gap is significant because managerial language reflects strategic priorities over the long term; it indicates resource allocation, highlights trade-offs, and shapes stakeholder expectations. We develop and test propositions that link firms' emphasis on OI partnership to the number of active projects across three R&D phases: discovery, experimentation, and commercialization. Using established topic modeling techniques, we analyze annual shareholder letters from 24 large pharmaceutical firms over 20 years to create a continuous, firm-year measure of OI partnership and correlate it with phase-level project counts. Fixed-effects negative binomial models are utilized to investigate whether the expected association patterns are observable in the data. Findings are consistent with a null association in the discovery phase but positive associations in the experimentation and commercialization phases, suggesting different influences across R&D phases, which are critical conditions for achieving project success. This study empirically demonstrates how a firm's emphasis on OI partnership aligns with project activities throughout the R&D pipeline, providing a process-oriented, phase-contingent perspective on OI. Theoretically, by presenting propositions and associational evidence, this work outlines expected relationships within an emerging theoretical domain. Practically, it offers actionable insights for managing external partnerships in high-uncertainty industries, highlighting the need for a nuanced approach to OI adoption to optimize innovation pipelines.